Journal of Pharmaceutical Analysis (Apr 2024)
Targeting the chromatin structural changes of antitumor immunity
- Nian-nian Li,
- Deng-xing Lun,
- Ningning Gong,
- Gang Meng,
- Xin-ying Du,
- He Wang,
- Xiangxiang Bao,
- Xin-yang Li,
- Ji-wu Song,
- Kewei Hu,
- Lala Li,
- Si-ying Li,
- Wenbo Liu,
- Wanping Zhu,
- Yunlong Zhang,
- Jikai Li,
- Ting Yao,
- Leming Mou,
- Xiaoqing Han,
- Furong Hao,
- Yongcheng Hu,
- Lin Liu,
- Hongguang Zhu,
- Yuyun Wu,
- Bin Liu
Affiliations
- Nian-nian Li
- Weifang People's Hospital, Weifang, Shandong, 261000, China; School of Life Sciences, Nankai University, Tianjin, 300071, China
- Deng-xing Lun
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Ningning Gong
- Weifang Traditional Chinese Medicine Hospital, Weifang, Shandong, 261000, China
- Gang Meng
- Shaanxi Key Laboratory of Sericulture, Ankang University, Ankang, Shaanxi, 725000, China
- Xin-ying Du
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- He Wang
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Xiangxiang Bao
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Xin-yang Li
- Guizhou Education University, Guiyang, 550018, China
- Ji-wu Song
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Kewei Hu
- Weifang Traditional Chinese Medicine Hospital, Weifang, Shandong, 261000, China
- Lala Li
- Guizhou Normal University, Guiyang, 550025, China
- Si-ying Li
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Wenbo Liu
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Wanping Zhu
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Yunlong Zhang
- School of Medical Imaging, Weifang Medical University, Weifang, Shandong, 261053, China
- Jikai Li
- Department of Bone and Soft Tissue Oncology, Tianjin Hospital, Tianjin, 300299, China
- Ting Yao
- School of Life Sciences, Nankai University, Tianjin, 300071, China; Teda Institute of Biological Sciences & Biotechnology, Nankai University, Tianjin, 300457, China
- Leming Mou
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Xiaoqing Han
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Furong Hao
- Weifang People's Hospital, Weifang, Shandong, 261000, China
- Yongcheng Hu
- Weifang People's Hospital, Weifang, Shandong, 261000, China; Corresponding author.
- Lin Liu
- School of Life Sciences, Nankai University, Tianjin, 300071, China; Corresponding author.
- Hongguang Zhu
- Weifang People's Hospital, Weifang, Shandong, 261000, China; Corresponding author.
- Yuyun Wu
- Xinqiao Hospital of Army Military Medical University, Chongqing, 400038, China; Corresponding author.
- Bin Liu
- Weifang People's Hospital, Weifang, Shandong, 261000, China; School of Life Sciences, Nankai University, Tianjin, 300071, China; Teda Institute of Biological Sciences & Biotechnology, Nankai University, Tianjin, 300457, China; Corresponding author. Teda Institute of Biological Sciences & Biotechnology, Nankai University, Tianjin, 300457, China.
- Journal volume & issue
-
Vol. 14,
no. 4
p. 100905
Abstract
Epigenomic imbalance drives abnormal transcriptional processes, promoting the onset and progression of cancer. Although defective gene regulation generally affects carcinogenesis and tumor suppression networks, tumor immunogenicity and immune cells involved in antitumor responses may also be affected by epigenomic changes, which may have significant implications for the development and application of epigenetic therapy, cancer immunotherapy, and their combinations. Herein, we focus on the impact of epigenetic regulation on tumor immune cell function and the role of key abnormal epigenetic processes, DNA methylation, histone post-translational modification, and chromatin structure in tumor immunogenicity, and introduce these epigenetic research methods. We emphasize the value of small-molecule inhibitors of epigenetic modulators in enhancing antitumor immune responses and discuss the challenges of developing treatment plans that combine epigenetic therapy and immunotherapy through the complex interaction between cancer epigenetics and cancer immunology.
